Analys

NANEXA: Phase I results position NEX-22 for licensing opportunities and a head start in long-acting GLP-1

Analys, Research

The positive results in Nanexa’s Phase I study for NEX-22, a once-monthly depot formulation of the GLP-1 analog liraglutide for type 2...

Read More

Lyft för Bonzun evolve ger stöd åt flerbent strategi

Analys, Analysartiklar

Den starka tillväxten (om än från mycket låga nivåer) i Bonzuns första rapport som noterat bolag skänker trovärdighet åt...

Read More

Loudspring’s portfolio company heading for stake in high volume Li-ion battery producer TeraFactory

Analys, Analysartiklar

With the next generation of Li-ion battery manufacturing, relying on the same method as paper production, TeraFactory aims for an annual...

Read More

GRANGEX: Steady progress in Norway, but new headwind in Sweden prompt additional patience from investors

Analys, Research

While Sydvaranger is progressing as scheduled, with a PEA planned for Q1’25 and a DFS by mid-2025, Dannemora has encountered a new...

Read More

CRUNCHFISH: Detailing the eight revenue opportunities ahead

Analys, Research

While the Q3’24 report did not contain any particular surprises in terms of financials, it did provide details on the eight revenue...

Read More

New strategy with payback on investments from 2022

Analys, Analysartiklar

With a new strategic plan for 2022-2026, a product portfolio geared to the forefront of technology, and strong double-digit market growth...

Read More

Unik och diversifierad utväxling på kryptoboomen

Analys, Analysartiklar

I takt med en smygande oro för stigande inflation har bitcoin och andra kryptovalutor klättrat till nya rekordnivåer. Hilbert erbjuder...

Read More

NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

Analys, Research

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly...

Read More

PROLIGHT: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships

Analys, Research

Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to...

Read More

For new research on growth stocks, sign up to our newsletter